SCHEMBL2811601

SCHEMBL2811601

C[C@H](N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)O.[Cu]

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.49
GHSR Q92847 3/20 0.43
NOD1 Q9Y239 1/20 0.38
ECE1 P42892 1/20 0.38
ERAP2 Q6P179 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38
LNPEP Q9UIQ6 1/20 0.38
GNPAT O15228 1/20 0.38
FOLH1 Q04609 1/20 0.38
CPB2 Q96IY4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2247594 1.00 SLC15A2 (0.49) SLC15A2GHSRNOD1ECE1ERAP2
SCHEMBL1959809 0.99 SLC15A2 (0.50) SLC15A2GHSRNOD1ECE1ERAP2
SCHEMBL5969770 0.99 SLC15A2 (0.50) SLC15A2GHSRNOD1ECE1ERAP2
SCHEMBL1959812 0.99 SLC15A2 (0.50) SLC15A2GHSRNOD1ECE1ERAP2
Hydrochloric Acid SCHEMBL7805623 0.98 SLC15A2 (0.49) SLC15A2GHSRNOD1ECE1ERAP2
SCHEMBL4590038 0.98 SLC15A2 (0.49) SLC15A2GHSRNOD1ECE1ERAP2
SCHEMBL4589288 0.98 SLC15A2 (0.49) SLC15A2GHSRNOD1ECE1ERAP2
Acetic Acid SCHEMBL9411947 0.97 SLC15A2 (0.48) SLC15A2GHSRNOD1ECE1ERAP2
SCHEMBL8000316 0.96 SLC15A2 (0.47) SLC15A2GHSRECE1ERAP2ERAP1
SCHEMBL8000305 0.96 SLC15A2 (0.47) SLC15A2GHSRECE1ERAP2ERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333159-B2 Topical DNA repair composition PHOTOMEDEX, INC. (US) 2016-05-10 US disclosed
US-20140335137-A1 Topical DNA Repair Composition PHARMA COSMETICS LABORATORIES LTD. (IL) 2014-11-13 US disclosed
US-20100249042-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS PROCYTE CORPORATION (US) 2010-09-30 US disclosed
EP-1545579-A1 COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND PHYTOCHEMICAL COMPOUNDS, AND METHODS RELATED THERETO PROCYTE CORPORATION (US) 2005-06-29 EP disclosed
EP-1434563-A1 METHODS FOR THE TREATMENT OF HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2004-07-07 EP disclosed
WO-2004014413-A1 COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND PHYTOCHEMICAL COMPOUNDS, AND METHODS RELATED THERETO PROCYTE CORPORATION (US) 2004-02-19 WO disclosed
US-20030134781-A1 Methods for the treatment of hyperpigmentation of skin PROCYTE CORPORATION 2003-07-17 US disclosed
WO-2003047543-A1 METHODS FOR THE TREATMENT OF HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2003-06-12 WO disclosed
EP-0765152-A1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1997-04-02 EP disclosed
WO-1995035085-A1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1995-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335137-A1 Topical DNA Repair Composition ERCC1, UNG, ERCC5 SLC15A2 2395/4885GHSR 4685/4885NOD1 3625/4885
US-20100249042-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS CUTA, TYR, EYA3 SLC15A2 2514/4885GHSR 529/4885NOD1 4770/4885
US-20030134781-A1 Methods for the treatment of hyperpigmentation of skin RBP1, RBP4, MC1R SLC15A2 1416/4885GHSR 345/4885NOD1 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.